Imunon Announces That An Abstract Highlighting New Overall Survival Data From Phase 2 Ovation 2 Study Of Imnn-001 To Treat Women With Newly Diagnosed Advanced Ovarian Cancer Was Accepted For Oral Presentation at the 2025 American Society of Clinical Oncol